| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| ln Vitro |
LIBX-A401 (0.38 ± 0.03 μM; maximum 50 μM; 10 μM) inhibited wild-type recombinant human ACSL4 with an IC50 of 0.38 ± 0.03 μM and a Kd of 0.72 ± 0.12 μM. It had no activity against recombinant human ACSL3 (IC50 > 50 μM) and no activity against PPARγ at 10 μM [1]. The IC50 values of LIBX-A401 against recombinant human ACSL4Q302M, ACSL4Q302A and ACSL4L325F mutants were 7.1 ± 0.6 μM, 2.4 ± 0.4 μM and 17.8 ± 3.8 μM, respectively, and the Kd values were 11.0 ± 1.6 μM, 8.6 ± 1.3 μM and 43.5 ± 5.4 μM, respectively [1]. LIBX-A401 (5 μM) can induce ATP-dependent changes in the thermal stability of wild-type recombinant human ACSL4, increasing its thermal stability by ΔTm to 5.3 ± 0.2 °C at a concentration of 5 μM [1]. LIBX-A401 (100 μM) can specifically bind to the fatty acid-gated domain peptide 313DTYIGYLPLAHVLELTAEISCFTYGCR339 of recombinant wild-type human ACSL4 in an ATP-dependent manner, which can be confirmed by competitive reduction assays labeled with photoaffinity probes [1]. LIBX-A401 (2.5 μM; pre-incubation for 24 hours) can protect HEK293 and HT-1080 cells from RSL3-induced ferroptosis [1]. LIBX-A401 (2.5 μM; pre-incubation for 4 hours) can protect LUHMES cells from arachidonic acid + Fe-induced ferroptosis and reduce lipid peroxidation levels [1]. LIBX-A401 (50 μM) does not have DPPH scavenging activity [1].
|
|---|---|
| Cell Assay |
Cell viability assay [1]
Cell Types: HEK293 and HT-1080 cells Tested Concentrations: 2.5 μM (pre-incubation) Incubation Duration: 24 hours (pre-incubation); 48 hours (RSL3 treatment) Experimental Results: Significantly inhibited RSL3-induced cell death. Compared with the untreated control group exposed to RSL3, higher cell viability was maintained. Cell viability assay [1] Cell Types: LUHMES cells Tested Concentrations: 2.5 μM (pre-incubation) Incubation Duration: 4 hours (pre-incubation); 48 hours (arachidonic acid + Fe treatment) Experimental Results: Significantly inhibited AA + Fe-induced cell death. Compared with the untreated control group exposed to AA + Fe, cell viability was maintained at a level comparable to that of ACSL4 siRNA transfected cells. |
| References |
| Molecular Formula |
C20H21NO4
|
|---|---|
| Molecular Weight |
339.39
|
| CAS # |
3111845-07-6
|
| Appearance |
White to off-white solid
|
| SMILES |
CN(CCOC1=CC=C(C=C1)/C=C/C(OC)=O)C(C2=CC=CC=C2)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~147.32 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of physiological saline: Dissolve 0.9 g of sodium chloride in double-distilled water and dilute to 100 mL to obtain clear physiological saline. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD saline (4°C, store for one week): Dissolve 2 g of SBE-β-CD powder in 10 mL of saline until completely dissolved and clear. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.37 mM)(saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9465 mL | 14.7323 mL | 29.4646 mL | |
| 5 mM | 0.5893 mL | 2.9465 mL | 5.8929 mL | |
| 10 mM | 0.2946 mL | 1.4732 mL | 2.9465 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
